Verrica Pharmaceuticals Inc. (VRCA) fundamentals score
Verrica Pharmaceuticals is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Currently, its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 4.7 out of 10, Weak long-term fundamentals
- Growth: 5.0/10
- Profitability: 3.3/10
- Financial health: 4.7/10
- Earnings quality: 4.3/10
- Valuation: 7.0/10
Scores are calculated from Verrica Pharmaceuticals Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10